Adam Bryant is a Senior Staff Specialist Haematologist at Liverpool Hospital in South Western Sydney and a Conjoint Senior Lecturer with the University of New South Wales. He is President and NSW Councillor of the Haematology Society of Australia and New Zealand.

At Liverpool Hospital, Adam leads the Myeloma and Plasma Cell Disorders Unit and serves as Deputy Director of the Transplant and Cellular Therapies Unit, where he is overseeing the development of the hospital’s standard-of-care CAR-T cell therapy program for myeloma.

Through the South Western Sydney Local Health District Haematology Clinical Research Unit, Adam has been Principal Investigator on numerous myeloma clinical trials, including industry-sponsored, cooperative group and collaborative studies. He is a member of the Myeloma Working Party of the Australasian Leukaemia and Lymphoma Group and the Medical and Scientific Advisory Group of Myeloma Australia.

His clinical and academic interests include multiple myeloma, plasma cell disorders, clinical trials, real-world evidence, treatment deliverability, toxicity mitigation, cellular therapy implementation, patient-centred care, and equitable access to advanced myeloma therapies.